Francisco Albuquerque

Francisco Albuquerque

Auto-generated profile, based on publicly available information

Francisco Albuquerque

Department of Cardiology, Hospital Santa Cruz, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2023 in Cardiovascular Ultrasound
Verified
Journal Article
Open access
PDF file
DGDaniel A Gomes
Daniel A Gomes
PLPedro M. Lopes
Pedro M. Lopes
PFPedro Freitas
Pedro Freitas
FAFrancisco Albuquerque
Francisco Albuquerque
CRCarla Reis
Carla Reis
MAMaria J. Andrade
Maria J. Andrade
Purpose: Chronic mitral regurgitation promotes left atrial (LA) remodeling. However, the significance of LA dysfunction in the setting of ventricular functional mitral regurgitation (FMR) has not been fully investigated. Our aim was to assess the prognostic impact of peak atrial longitudinal strain (PALS), a surrogate of LA function, in patients with FMR and reduced left ventricular ejection fraction (LVEF). Methods: Patients with at least mild ventricular FMR and LVEF < 50% under optimized medical therapy who underwent transthoracic echocardiography at a single center were retrospectively identified in the laboratory database. PALS was assessed by 2D speckle tracking in the apical 4-chamber view and the study population was divided in two groups according to the best cut-off value of PALS, using receiver operating characteristics (ROC) curve analysis. The primary endpoint-point was all-cause mortality. Results: A total of 307 patients (median age 70 years, 77% male) were included. Median LVEF was 35% (IQR: 27 – 40%) and median effective regurgitant orifice area (EROA) was 15mm2 (IQR: 9 – 22mm2). According to current European guidelines, 32 patients had severe FMR (10%). During a median follow-up of 3.5 years (IQR 1.4 – 6.6), 148 patients died. The unadjusted mortality incidence per 100 persons-years increased with progressively lower values of PALS. On multivariable analysis, PALS remained independently associated with all-cause mortality (adjusted hazard ratio 1.052 per % decrease; 95% CI: 1.010 – 1.095; P = 0.016), even after adjustment for several (n = 14) clinical and echocardiographic confounders. Conclusion: PALS is independently associated with all-cause mortality in patients with reduced LVEF and ventricular FMR. Graphical

20 March 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MPMariana Sousa Paiva
Mariana Sousa Paiva
FGFrancisco Gama
Francisco Gama
SCSamuel Azevedo Chaves
Samuel Azevedo Chaves
PLPedro M. Lopes
Pedro M. Lopes
FAFrancisco Albuquerque
Francisco Albuquerque
PAPedro Pulido Adragão
Pedro Pulido Adragão
Background and Aim: Left ventricular thrombus (LVT) is a common complication of myocardial infarction (MI) and heart failure with reduced ejection fraction (HFrEF), typically managed with vitamin K antagonists (VKAs) for up to six months. However, data on direct oral anticoagulants (DOACs) for LVT treatment remain limited and conflicting. This study evaluates the effectiveness and safety of DOACs compared to warfarin for LVT resolution. Methods: We conducted a single-center retrospective cohort study of consecutive patients diagnosed with LVT from January 2010 to May 2024. The primary outcome was LVT resolution at 24 months. Safety outcomes included major bleeding and thromboembolic events. Diagnosis and follow-up were performed via echocardiography, with cardiac magnetic resonance and computed tomography as needed. Anticoagulant type, dose, duration, and concurrent antiplatelet therapy were at the treating physician’s discretion. Results: Among 171 patients (82.5% male, mean age 59.8 ± 14.7 years), 99 received DOACs and 72 received warfarin. LVT resolution was higher with DOACs (66.7% vs. 50%, HR 2.0, 95% CI 1.07–3.73, p = 0.029), with a trend toward faster thrombus resolution (185 vs. 220 days, p = 0.214) though statistically not significant. DOAC use remained an independent predictor of LVT resolution, regardless of antiplatelet use. Major bleeding (2.9%), thromboembolic events (5.3%), and mortality (5.3%) were similar between groups. Conclusions: DOAC therapy was associated with higher LVT resolution rates and a comparable safety profile to warfarin. Further randomized clinical trials are warranted to validate these findings.

19 June 2023 in Clinical Research in Cardiology
Verified
Journal Article
Closed access
PDF file
FAFrancisco Albuquerque
Francisco Albuquerque
DGDaniel A Gomes
Daniel A Gomes
JFJorge Ferreira
Jorge Ferreira
PGPedro de Araújo Gonçalves
Pedro de Araújo Gonçalves
PLPedro M. Lopes
Pedro M. Lopes
MAManuel de Sousa Almeida
Manuel de Sousa Almeida

14 March 2022 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
PLPedro M. Lopes
Pedro M. Lopes
FAFrancisco Albuquerque
Francisco Albuquerque
AFAntónio Ferreira
António Ferreira
MTMarisa Trabulo
Marisa Trabulo
A young man in his late 20s was presented with acute chest pain, concave ST elevation in lateral and inferior leads on ECG and elevated cardiac troponin. A thorough clinical history was notable for clenbuterol abuse. Transthoracic echocardiography revealed a small area of hypokinesia in the inferior wall and cardiac magnetic resonance supported the diagnosis of acute myocarditis revealing signs of myocardial oedema and subepicardial delayed enhancement. The patient was managed conservatively and had an uneventful clinical course. Awareness of the possibility of clenbuterol myocardial toxicity in young men admitted due to chest pain is essential to prompt diagnosis and management of this condition.

4 March 2024 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
PDF file
DGDaniel A Gomes
Daniel A Gomes
MPMariana Sousa Paiva
Mariana Sousa Paiva
PFPedro Freitas
Pedro Freitas
FAFrancisco Albuquerque
Francisco Albuquerque
MLMaria Rita Lima
Maria Rita Lima
MMMiguel Mendes
Miguel Mendes
Resumo Fundamento: As diretrizes da Sociedade Europeia de Cardiologia recomendam um nível de colesterol LDL (LDL-C) < 55 mg/dL para pacientes com doença cardiovascular estabelecida. Embora a fórmula de Friedewald ainda seja amplamente utilizada para estimar o LDL-C, a fórmula mais recente de Martin-Hopkins mostrou maior precisão. Objetivos: Nosso objetivo foi avaliar: A) a proporção de pacientes que atingiram a meta de LDL-C e as terapias utilizadas em um centro terciário; B) o impacto da utilização do método de Martin-Hopkins

14 August 2023 in The American Journal of Cardiology
Verified
Journal Article
Closed access
FAFrancisco Albuquerque
Francisco Albuquerque
PLPedro M. Lopes
Pedro M. Lopes
PFPedro Freitas
Pedro Freitas
PGPedro de Araújo Gonçalves
Pedro de Araújo Gonçalves
JPJoão Presume
João Presume
AFAntónio M. Ferreira
António M. Ferreira